NO20054336D0 - Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer - Google Patents

Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Info

Publication number
NO20054336D0
NO20054336D0 NO20054336A NO20054336A NO20054336D0 NO 20054336 D0 NO20054336 D0 NO 20054336D0 NO 20054336 A NO20054336 A NO 20054336A NO 20054336 A NO20054336 A NO 20054336A NO 20054336 D0 NO20054336 D0 NO 20054336D0
Authority
NO
Norway
Prior art keywords
asthma
allergic
diagnosis
compositions
treatment
Prior art date
Application number
NO20054336A
Other languages
English (en)
Other versions
NO20054336L (no
Inventor
Michael R Bowman
Debra Ellis
Maximillian T Follettie
Aaron Winkler
Cara Williams
Heng Chen
Wei Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054336D0 publication Critical patent/NO20054336D0/no
Publication of NO20054336L publication Critical patent/NO20054336L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
NO20054336A 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer NO20054336L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45139603P 2003-03-04 2003-03-04
US47587003P 2003-06-05 2003-06-05
PCT/US2004/006470 WO2005003164A2 (en) 2003-03-04 2004-03-04 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases

Publications (2)

Publication Number Publication Date
NO20054336D0 true NO20054336D0 (no) 2005-09-20
NO20054336L NO20054336L (no) 2005-12-02

Family

ID=33567303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054336A NO20054336L (no) 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Country Status (11)

Country Link
US (2) US20040234517A1 (no)
EP (1) EP1599587A2 (no)
JP (1) JP2007537984A (no)
KR (1) KR20050106483A (no)
AU (1) AU2004253846A1 (no)
BR (1) BRPI0408004A (no)
CA (1) CA2517684A1 (no)
MX (1) MXPA05009251A (no)
NO (1) NO20054336L (no)
RU (2) RU2005130636A (no)
WO (1) WO2005003164A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005620A2 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
US20100021953A1 (en) * 2005-08-03 2010-01-28 Astrazeneca Ab Method for Identifying an Agent that Modulates Arginine Transport in a Chondrocyte
JP2009511586A (ja) * 2005-10-11 2009-03-19 ワシントン・ユニバーシティ 気道分泌過多を治療するための組成物および方法
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
DE602007013691D1 (de) * 2007-03-06 2011-05-19 Rachid Ennamany Zusammensetzung auf Basis von Rutin und L-Lysin
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
EP3257953B1 (en) * 2009-03-12 2018-09-26 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
GB201007556D0 (en) * 2010-05-06 2010-06-23 Wetenschappelijk En Tech Ct Va Methods and compositions for textile layers and coatings
NO2576783T3 (no) * 2010-05-26 2018-04-28
WO2011163499A2 (en) * 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
KR20230057404A (ko) * 2020-08-26 2023-04-28 실라 세라퓨틱 인크. 흡입 가능한 치료제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
DE3280400D1 (de) * 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
WO2002015895A2 (en) * 2000-08-24 2002-02-28 The Regents Of The University Of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
EP1527196A4 (en) * 2002-03-01 2007-03-14 Childrens Hosp Medical Center TREATMENT OF ASTHMA OR ALLERGIES
US20040057926A1 (en) * 2002-03-12 2004-03-25 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
WO2004073623A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions

Also Published As

Publication number Publication date
RU2008145510A (ru) 2010-05-27
MXPA05009251A (es) 2005-10-19
NO20054336L (no) 2005-12-02
US20090156537A1 (en) 2009-06-18
EP1599587A2 (en) 2005-11-30
WO2005003164A3 (en) 2005-05-12
RU2005130636A (ru) 2006-05-10
AU2004253846A1 (en) 2005-01-13
WO2005003164A9 (en) 2006-07-20
US20040234517A1 (en) 2004-11-25
KR20050106483A (ko) 2005-11-09
WO2005003164A2 (en) 2005-01-13
JP2007537984A (ja) 2007-12-27
BRPI0408004A (pt) 2006-02-14
CA2517684A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20054336D0 (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
DK1608374T3 (da) 2-Phenoxy- og 2-phenylsulfanylbenzensulfonamidderivater med CCR3-antagonistisk aktivitet til behandling af astma og andre inflammatoriske eller immunologiske sygdomme
CY2021009I1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1889065T3 (da) Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
IS8123A (is) Ný heteróhringlaga efnasambönd sem eru gagnleg í meðhöndlun á bólgu- og ofnæmissjúkdómum; aðferðir til að framleiða þau og lyfjablöndur sem innihaldaþau
DK1673104T4 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1581119T3 (da) Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
DE502005007427D1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
ATE448232T1 (de) Substituierte heterozyklen
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
EA200601462A1 (ru) Соединения для лечения заболеваний
NO20074648L (no) 5-fenyl-pentansyrederivater som matrise metalloproteinaseinhibitorer til behandling av astma og andre sykdommer
NO20014648D0 (no) Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
EP1765331A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application